QuidelOrtho Corporation (LON:0A55)

London flag London · Delayed Price · Currency is GBP · Price in USD
43.50
-0.14 (-0.31%)
At close: Jan 31, 2025
-38.01%
Market Cap 1.45B
Revenue (ttm) 2.14B
Net Income (ttm) -277.08M
Shares Out n/a
EPS (ttm) -4.12
PE Ratio n/a
Forward PE 11.06
Dividend n/a
Ex-Dividend Date n/a
Volume 2
Average Volume 177
Open 43.09
Previous Close 43.64
Day's Range 43.09 - 43.50
52-Week Range 29.91 - 69.67
Beta n/a
RSI 49.59
Earnings Date Jul 30, 2025

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 1979
Employees 6,600
Stock Exchange London Stock Exchange
Ticker Symbol 0A55
Full Company Profile

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Financial numbers in USD Financial Statements

News

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO , July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company"...

7 days ago - PRNewsWire

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance― ―Company Plans to Discontinue Savanna® Platform Development― ―Company Reaffirms Full Year 2025 Financial Guidance ― ―Company to Hos...

5 weeks ago - PRNewsWire

QuidelOrtho to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

7 weeks ago - Business Wire

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight

New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...

2 months ago - Benzinga

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

QuidelOrtho's stock jumped after Q1 2025 earnings beat, but long-term growth remains weak. Check out why QDEL stock is downgraded to hold.

2 months ago - Seeking Alpha

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...

2 months ago - Seeking Alpha

QuidelOrtho Reports First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

2 months ago - Business Wire

QuidelOrtho to Report First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...

2 months ago - Business Wire

QuidelOrtho® Introduces Results Manager™ System

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address t...

4 months ago - Business Wire

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

5 months ago - Business Wire

T. Rowe Price Investment Management, Inc. Increases Stake in QuidelOrtho Corp

T. Rowe Price Investment Management, Inc. Increases Stake in QuidelOrtho Corp

5 months ago - GuruFocus

Rubric Capital Management LP Increases Stake in QuidelOrtho Corp

Rubric Capital Management LP Increases Stake in QuidelOrtho Corp

5 months ago - GuruFocus

QuidelOrtho (QDEL) Stock Moves on Earnings Beat

QuidelOrtho (QDEL) Stock Moves on Earnings Beat

5 months ago - GuruFocus

QuidelOrtho Corp (QDEL) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and ...

QuidelOrtho Corp (QDEL) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic Growth Initiatives

5 months ago - GuruFocus

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President...

5 months ago - Seeking Alpha

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

5 months ago - Business Wire

QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results

QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results

6 months ago - GuruFocus

QuidelOrtho announces preliminary Q4 2024 revenue in range of $702 million to $707 million

QuidelOrtho expects Q4 2024 revenues to exceed consensus estimates. Non-respiratory revenue projected at $561-563 million.

6 months ago - Seeking Alpha